Tumour Spheroid Model for Antibody-Targeted Therapy
Author Information
Author(s): K.A. Walker, T. Murray, T.E. Hilditch, T.E. Wheldon, A. Gregor, I.M. Hann
Primary Institution: Beatson Oncology Centre, Glasgow
Hypothesis
Can a tumour spheroid model effectively evaluate antibody-targeted radiotherapy for micrometastases?
Conclusion
The study found that the effectiveness of antibody-targeted irradiation on neuroblastoma spheroids increases with the activity of the radiolabelled antibody.
Supporting Evidence
- The study demonstrated a dose-response relationship between the activity of 131I-UJ13A and the effectiveness in sterilizing spheroids.
- Control treatments with Na[131I] showed no significant effect on spheroid growth.
- Longer incubation times with 131I-UJ13A resulted in a higher proportion of sterilized spheroids.
Takeaway
Researchers grew tiny cancer cell clusters and tested a special treatment to see if it could stop them from growing. They found that the treatment worked better when they used more of it.
Methodology
Human neuroblastoma cells were grown as spheroids and treated with radiolabelled antibodies to evaluate their growth response.
Potential Biases
Potential bias in the selection of antibody treatments and controls.
Limitations
The study primarily focused on one type of cancer cell line and may not be generalizable to all cancers.
Participant Demographics
Human neuroblastoma cell line NB1-G was used.
Statistical Information
P-Value
p<0.05
Confidence Interval
95%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website